EpiPen Recent News
Imprimis Challenges Mallinckrodt's Acthar
How Did A Maligned Mylan Surprise To The Upside With 2017 Outlook?
Short Sellers Bet Against Generic EpiPen
Mylan's EpiPen Dropped From Cigna's Coverage List
How Does Mylan's $300 Choice Compare To Other Generic EpiPens?
Andrew Left Challenges Mallinckrodt, Compares Acthar To The EpiPen
Mylan's Q3 Report Tries, Fails To Shift Focus Away From EpiPen Controversy
The Things You Need To Know Ahead Of Mylan's Q3 Earnings
Mylan Surrenders Some Of Its Gains From EpiPen Settlement
Mylan Analysts Respond Positively Following EpiPen Classification Settlement
After-Hours: 2 Stocks On The Move On Another Slow Friday Afternoon
Epipen's Profits Are Actually A Lot Higher Than Mylan Originally Told Congress
USA Today On EpiPen Saga: Calling It 'Controversial' Is Far From Haphazard
Controversy Pullback Offers Good Entry Point For Mylan
Mylan's CEO Showed 'Very Little Empathy,' Bill George Says
Mylan Investors Should Be Asking Where (And Who) Robert Coury Is
Another Election Year View On Healthcare ETFs
MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says
Mylan Announces $300 Version Of EpiPen
Pharma Companies Are Spending Millions To Sustain High Drug Prices
Mylan Is Offering An EpiPen Savings Card, But A Lot Of People Will Still Get Screwed
Selling Pressure Continues For Mylan
Mylan 'Took The Sting' Out Of The EpiPen Controversy